Zacks

Zacks Small Cap Analysis – TELO Declares Promising Getting older Reversal Check Outcomes – Model Slux

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Prescription drugs (NASDAQ:TELO) is a preclinical stage biopharmaceutical firm creating a product designed to elongate the DNA’s protecting telomere caps. Beforehand reported preclinical assessments have proven proof that Telomir-1, the corporate’s major remedy, can lengthen telomeres and preliminary animal testing illustrates the potential … Read more

Zacks Small Cap Analysis – LGVN Takes Steps Towards Success – Model Slux

by

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) has been beneath the management of a brand new CEO for simply over a 12 months, with Mr. Hashad not too long ago issuing a letter to shareholders marking the milestone. We now have been telling buyers in regards to the nice … Read more

Zacks Small Cap Analysis – SNGX: Settlement with EMA on Second Confirmatory Trial for HyBryte… – Model Slux

by
Zacks Small Cap Analysis – SNGX: Settlement with EMA on Second Confirmatory Trial for HyBryte… – Model Slux

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Enterprise Replace Reaches Settlement with European Medicines Company on Second Confirmatory Trial for HyBryte On April 3, 2024, Soligenix, Inc. (NASDAQ:SNGX) introduced it has reached settlement with the European Medicines Company (EMA) on the important thing design parts for a confirmatory Part 3 trial … Read more

Zacks Small Cap Analysis – IMNN: IND Utility Submitted for Section 1/2 Trial of Seasonal COVID-19 Vaccine… – Model Slux

by

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace Replace on IMNN-101 Imunon, Inc. (NASDAQ:IMNN) is growing IMNN-101, which is a COVID-19 seasonal vaccine booster based mostly on the corporate’s PlaCCine know-how. It’s a DNA vaccine that addresses plenty of limitations of present vaccines, together with the sturdiness of antigen expression, … Read more

Zacks Small Cap Analysis – CRVO: $150 Million Financing Strengthens Steadiness Sheet; Topline Knowledge for Part 2b Trial in 4Q24… – Model Slux

by
Zacks Small Cap Analysis – CRVO: 0 Million Financing Strengthens Steadiness Sheet; Topline Knowledge for Part 2b Trial in 4Q24… – Model Slux

By David Bautz, PhD NASDAQ:CRVO READ THE FULL CRVO RESEARCH REPORT Enterprise Replace Biomarker Knowledge Introduced at AD/PD 2024 On March 5, 2024, CervoMed Inc. (NASDAQ:CRVO) introduced the presentation of biomarker knowledge from the AscenD-LB Part 2a trial of neflamapimod in sufferers with dementia with Lewy our bodies (DLB) was featured in a poster presentation … Read more

x